Inovio Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>IP</div>
INO -- USA Stock  

USD 16.94  1.57  10.21%

As many of us are excited about healthcare space, it is fair to outline Inovio Pharmaceuticals. We will evaluate why recent Inovio Pharmaceuticals price moves suggest a bounce in October. Is the firm current valuation justified? We will cover Inovio Pharmaceuticals valuation to give you a better outlook on taking a position in the stock.
Published over a week ago
View all stories for Inovio Pharmaceuticals | View All Stories
Is Inovio Pharmaceuticals outlook positive for October 2020?
This firm has 101.02 M in debt with debt to equity (D/E) ratio of 0.54, which is OK given its current industry classification. The company has a current ratio of 9.86, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. On a scale of 0 to 100, Inovio Pharmaceuticals holds a performance score of 3. The company retains a Market Volatility (i.e. Beta) of 0.1593, which attests to not very significant fluctuations relative to the market. Let's try to break down what Inovio's beta means in this case. As returns on the market increase, Inovio Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Inovio Pharmaceuticals will be expected to be smaller as well. Although it is vital to follow Inovio Pharmaceuticals current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By evaluating Inovio Pharmaceuticals technical indicators, you can presently evaluate if the expected return of 0.48% will be sustainable into the future. Please utilizes Inovio Pharmaceuticals maximum drawdown, as well as the relationship between the expected short fall and rate of daily change to make a quick decision on whether Inovio Pharmaceuticals current trending patterns will revert.
We determine the current worth of Inovio Pharmaceuticals using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Inovio Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Inovio Pharmaceuticals's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Inovio Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inovio Pharmaceuticals. We calculate exposure to Inovio Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Inovio Pharmaceuticals's related companies.

Inovio Pharmaceuticals Investment Alerts

Inovio investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Inovio Pharmaceuticals performance across your portfolios.Please check all investment alerts for Inovio

Inovio Pharmaceuticals Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Inovio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inovio Pharmaceuticals competition to find correlations between indicators driving the intrinsic value of Inovio.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Inovio Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

Sale by Laurent Humeau of 19467 shares of Inovio Pharmaceuticals

Legal trades by Inovio Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Inovio insider trading alert for sale of common stock by Laurent Humeau, Chief Scientific Officer, on 12th of August 2020. This event was filed by Inovio Pharmaceuticals In with SEC on 2020-08-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Inovio Pharmaceuticals

Inovio Pharmaceuticals reported the last year's revenue of 2.74 M. Reported Net Loss for the year was (222 M) with loss before taxes, overhead, and interest of (82.01 M).

Margins Breakdown

Inovio profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Inovio Pharmaceuticals itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Inovio Pharmaceuticals profit margins.
Operating Margin(84.45)
EBITDA Margin(26.5)
Gross Margin0.89
Profit Margin(29.79)


Inovio Pharmaceuticals Earnings Before Interest Taxes and Depreciation Amortization EBITDA is quite stable at the moment. Further, Inovio Pharmaceuticals Revenue Per Employee is decreasing over the last 8 years.

Over 3 percent rise for Inovio Pharmaceuticals. What does it mean for institutional investors?

The total risk alpha is down to -0.82 as of today. Inovio Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Inovio Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Inovio Pharmaceuticals volatility.

Our Conclusion on Inovio Pharmaceuticals

Whereas other companies under the biotechnology industry are still a bit expensive, Inovio Pharmaceuticals may offer a potential longer-term growth to institutional investors. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to exit some or all of your Inovio Pharmaceuticals holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Inovio Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Inovio Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com